CDEK
← All drugs Report issue

interferon beta-1a

Trade name: Avonex

Recombinant proteinapprovedOrphan Drug FDA

Approved

May 17, 1996

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis (MS). It is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some research indicates that interferon injections may result in an 18–38% reduction in the rate of MS relapses. — Wikipedia

Clinical trial activity

14 trials · 22 clinical orgs · 3 marketing orgs

Phase 1
2
Phase 2
12
Phase 3
4
Phase 4
0

Earliest trial started Dec 20, 2017 (NCT05242133)

Timeline

1990s

  1. Dec 16, 1991

    Orphan Drug Designation

  2. May 17, 1996

    Biogen — Earliest FDA Approval

  3. May 17, 1996

    Biogen — Marketing Organization

  4. May 17, 1996

    Biogen — NDA Secondary Org

  5. May 17, 1996

    Biogen — NDA Organization

2000s

  1. Mar 7, 2002

    Serono — Marketing Organization

  2. Mar 7, 2002

    Merck Serono — NDA Secondary Org

2010s

  1. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedMay 17, 1996

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • avonex
  • avonex
  • avonex
  • avonex
  • beta interferon
  • beta-interferon
  • fibroblast interferon
  • interfb1a
  • interf b 1a
  • interferon beta
  • interferon beta
  • interferon-beta
  • interferon beta 1
  • interferon beta-1
  • interferon beta 1a
  • interferon beta 1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon beta-1a
  • interferon-beta-1a
  • interferon-beta-1a
  • interferon beta-1a,recombinant
  • interferon beta-1a (recombinant human)
  • interferon beta natural
  • neoferon
  • rebif
  • rebif
  • rebif
  • β-interferon

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07189325Phase 3Sep 30, 2025University of Montpellier
NCT06999603Phase 2Sep 2, 2025Synairgen Research Ltd.
NCT05936229Phase 1/Phase 2 (Phase 2)Apr 1, 2025Faron Pharmaceuticals Ltd, University of Washington
NCT06510426Phase 2Jul 14, 2024Tel Aviv University
NCT06019130Phase 2Jan 10, 2023Deutsche Krebshilfe e.V., German Society for Pediatric Oncology and Hematology GPOH gGmbH, RWTH Aachen University
NCT05298670Phase 2Feb 1, 2022German University in Cairo
NCT04727424Phase 3Jan 19, 2021Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA, Cytel Inc., Eiger BioPharmaceuticals, Fast Grants, McMaster University, RainWater Foundation
NCT04732949Phase 3Jan 12, 2021Moorgreen Hospital, Southampton, Synairgen Research Ltd.
NCT04615962Phase 1Jan 1, 2021Seanergy Ltd.
NCT04449380Phase 2Nov 2, 2020Ospedale San Raffaele, Vita-Salute University of Milano. Italy
NCT04521400Phase 2Aug 20, 2020Shahid Beheshti University of Medical Sciences
NCT05024006N/AApr 23, 2020University of the Philippines
NCT04385095Phase 2Mar 16, 2020Synairgen Research Ltd.
NCT05242133Phase 3Dec 20, 2017Cinnagen
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Synairgen Research Ltd.For profit3322020
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDAAcademic/Hospital1112021
CinnagenFor profit1112017
Cytel Inc.For profit1012021
Deutsche Krebshilfe e.V.Academic/Hospital1012023
Eiger BioPharmaceuticalsFor profit1012021
Faron Pharmaceuticals LtdFor profit1012025
Fast GrantsAcademic/Hospital1012021
German Society for Pediatric Oncology and Hematology GPOH gGmbHAcademic/Hospital1112023
German University in CairoAcademic/Hospital1112022
McMaster UniversityAcademic/Hospital1012021
Moorgreen Hospital, SouthamptonAcademic/Hospital1012021
Ospedale San RaffaeleAcademic/Hospital1112020
RainWater FoundationAcademic/Hospital1012021
RWTH Aachen UniversityAcademic/Hospital1012023
Seanergy Ltd.For profit1112021
Shahid Beheshti University of Medical SciencesAcademic/Hospital1112020
Tel Aviv UniversityAcademic/Hospital1112024
University of MontpellierAcademic/Hospital1112025
University of the PhilippinesAcademic/Hospital1112020
22 organizations
Page 1 / 2

Marketing (5)

OrganizationOrg typeRelationshipDate
BiogenFor profitMKTGMay 17, 1996
BiogenFor profitNDA2May 17, 1996
BiogenFor profitNDAMay 17, 1996
Merck SeronoFor profitNDA2Mar 7, 2002
SeronoFor profitMKTGMar 7, 2002